Samaritan Pharmaceuticals Begins Trading On OTC Bulletin Board Under Ticker Symbol SPHC

[~MaryO~]

http://money.cnn.com/news/newsfeeds/articl...wire/133152.htm

 

Samaritan Pharmaceuticals Begins Trading On OTC Bulletin Board Under Ticker Symbol SPHC

Prime Newswire

December 17, 2007: 10:10 AM EST

 

LAS VEGAS, Dec. 17, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals, Inc. (OTCBB:SPHC) (http://www.samaritanpharma.com), a biopharmaceutical company focused on developing innovative therapeutics in the areas of CNS, cancer, cardiovascular, and infectious diseases, has commenced trading on the Over-the-Counter (OTC) Bulletin Board under the ticker symbol SPHC, effective at the opening of trading today.

 

"As we move forward with the development of new life-saving drugs that offer a substantial benefit over what is already on the market, we believe Samaritan is well-positioned for growth," commented Dr. Janet Greeson, CEO of Samaritan. "In addition to the strength of our drug development activities, we are also increasing our overseas revenue generating pharmaceutical business. We remain determined to leave a legacy of bringing memory-restoring and new life-saving drugs to suffering patients, and look forward to communicating Samaritan's progress to shareholders."

 

Samaritan Pharmaceuticals: "Transforming Today's Science Into Tomorrow's Cures..."

 

Samaritan Pharmaceuticals is an entrepreneurial biopharmaceutical company that concentrates its efforts toward commercializing new innovative therapeutic drugs that offer a substantial for suffering patients. Samaritan has partnered its Phase II/III oral HIV viral-entry inhibitor drug. Its promising memory-restoring Alzheimer's drug Caprospinol expects to enter a Phase I clinical trial after acute toxicity study and its High Stress Cortisol drug to counteract Cushing's disease expects to enter Phase II clinical trials. Samaritan has several drugs it is preparing for FDA IND status; it is evaluating the use of SP-1000 for hypercholesterolemia patients and the use of SP-30 as an ``oral treatment'' for Hepatitis-C. In addition, Samaritan has acquired the marketing and sales rights to sell eleven revenue-generating products in various Eastern European countries.

 

The Samaritan Pharmaceuticals Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2670

 

Disclaimer

 

The company disclaims any information created by an outside party and endorses only information communicated by its press releases, filings, and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-Q filed August 13, 2007. The company undertakes no duty to update forward-looking statements.

 

CONTACT: The Investor Relations Group

Investor Relations:

Adam Holdsworth

Erica Ruderman

Rachel Colgate

212-825-3210